iRhythm(NASDAQ) IRTC

iRhythm makes small, wearable heart monitors that stick to a patient's chest like a patch. These devices help doctors find irregular heartbeats by recording every single beat for up to two weeks. The system uses smart software to find health problems that traditional short-term tests might miss.

What iRhythm Offers Patients

• Zio monitor and XT: Wearable, wire-free patches that record heart data continuously for up to 14 days; these long-term continuous monitoring services accounted for approximately 83% of revenue in 2025.
• Zio AT: A mobile cardiac telemetry system that sends heart data to a clinical center in real-time for patients who need closer monitoring.
• ZEUS System: A cloud-based platform using artificial intelligence to analyze millions of heartbeats and create diagnostic reports for physicians.
• ZioSuite: Digital tools including a web portal and mobile apps that let doctors and patients view heart rhythm data and symptoms.

Recent Strategic Moves

• Entered a technology license agreement with BioIntelliSense, Inc. in August 2024 to develop next-generation sensors for blood pressure and oxygen levels.
• Achieved a regulatory milestone in June 2025 related to the BioIntelliSense, Inc. partnership, leading to the cancellation of $10 million in promissory notes.
• Received regulatory approval from the Japan Pharmaceuticals and Medical Devices Agency in 2024 to launch the Zio system in the Japanese market.
• Expanded European operations by launching products in Austria, the Netherlands, Spain, and Switzerland during 2025.
• Submitted a 510(k) application to the FDA in the third quarter of 2025 for a new mobile cardiac telemetry device.

What Makes the Technology Different

The company maintains a massive database of nearly three billion hours of curated heartbeat data, which trains its artificial intelligence to reach clinical accuracy levels similar to cardiologists. Its patch design achieves high patient compliance, with users typically wearing the device for over 13 days of a 14-day prescribed period.

The Latest Financial Facts

• Revenue reached $208.9 million in Q4 2025, up 27.1% from the same period in 2024.
• Net income turned positive at $5.6 million in Q4 2025, up 518.5% from a loss in Q4 2024.
• Operating cash flow grew to $26.2 million in Q4 2025, a 36.3% increase year-over-year.
• Gross profit rose to $148.1 million in Q4 2025, up 28.7% from the previous year.

Evolution of the Business

iRhythm has transitioned from a startup focusing on a single heart patch to a global digital healthcare provider using artificial intelligence to manage population health. The company is now expanding its platform to address broader conditions like sleep apnea and heart failure through new sensor partnerships.